Medicare price rule could hit Keytruda and Opdivo subcutaneous launches

Medicare price rule could hit Keytruda and Opdivo subcutaneous launches

Key Takeaways

• Keytruda (pembrolizumab) and Opdivo (nivolumab) are expected to be eligible for selection in the 2027 Medicare price negotiation round for the 2029 initial price applicability year.
• KEYTRUDA QLEX is indicated for unresectable or metastatic melanoma, and OPDIVO QVANTIG is indicated for intermediate or poor risk advanced renal cell carcinoma.
• Medicare currently pays physicians Average Sales Price (ASP) plus 6% for drugs administered under Part B.

IntelligenceRegulatory Impact▾

Medicare decisions frame this story. Regulatory relevance is high for cancer, with Keytruda and Opdivo most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.

What Changed

The proposed Medicare drug price rule does not explicitly name Keytruda or Opdivo, but both checkpoint inhibitors are expected to be eligible for selection in the 2027 Medicare price negotiation round for the 2029 initial price applicability year. The 2027 selection window establishes when these drugs could enter the Medicare negotiation process.

IntelligenceCompetitive Intelligence▾

CMS are directly implicated. Competitive pressure reads medium — compare pipeline positioning and partnership scouting against signals in this story.

Clinical Profile and Approved Formulations

Merck's Keytruda has received 39 FDA approvals across 16 tumor and 2 tumor-agnostic indications. KEYTRUDA QLEX, a combination of pembrolizumab and berahyaluronidase alfa, is indicated for the treatment of adult patients with unresectable or metastatic melanoma.

Bristol Myers Squibb's Opdivo has similarly broad utility across oncology indications. OPDIVO QVANTIG, a combination of nivolumab and hyaluronidase, is indicated for the treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma.

IntelligenceMarket Signals▾

Commercial pull is high and investment relevance high for cancer. Expect implications for pricing, access, and launch sequencing.

Active Clinical Development

NCT03698019, a Phase 2 study sponsored by the National Cancer Institute, compares pembrolizumab administration after surgery versus both before and after surgery for high-risk melanoma, and is currently active but not recruiting. NCT06364917 (DISCERN) is a Phase 2 trial sponsored by the University of Alabama at Birmingham investigating dual versus single immune checkpoint blockade in PD-L1 negative non-small cell lung cancer and is actively recruiting.

In Hodgkin lymphoma, NCT03618550, a Phase 2 study at Memorial Sloan Kettering Cancer Center, is evaluating second-line pembrolizumab plus GVD for relapsed or refractory Hodgkin lymphoma and is recruiting.

NCT06203600, the PARAMUNE trial sponsored by the National Cancer Institute, is a Phase 2/3 study adding nivolumab to usual treatment for people with advanced stomach or esophageal cancer and is recruiting.

IntelligenceStrategic Takeaways▾

Keytruda (pembrolizumab) and Opdivo (nivolumab) are expected to be eligible for selection in the 2027 Medicare price negotiation round for the 2029 initial price applicability year . KEYTRUDA QLEX is indicated for unresectable or metastatic melanoma , and OPDIVO QVANTIG is indicated for intermediate or poor risk advanced renal cell carcinoma. Medicare currently pays physicians Average Sales Price (ASP) plus 6% for dr

Medicare Reimbursement and the 2027 Selection Window

Medicare pays physicians ASP plus 6% for drugs they administer under Part B. The 2027 selection window for IPAY 2029 establishes when Keytruda and Opdivo become eligible for the Medicare negotiation process. Until that round occurs, the current ASP-based reimbursement structure remains in effect.

Frequently Asked Questions

What to Watch Next

The 2027 Medicare price negotiation selection cycle will determine whether Keytruda, Opdivo, or both are chosen for negotiation. Ongoing clinical trials across melanoma, non-small cell lung cancer, Hodgkin lymphoma, and gastric cancer will continue to generate data on pembrolizumab and nivolumab.

Related profiles

• KEYTRUDA
• OPDIVO

Related coverage

• Prescription Drug Freight Fraud June 2026 report: what the record shows
• Takeda TYK2 drug tops Bristol Myers’ Sotyktu in psoriasis head-to-head test
• Medicare GLP-1 coverage 2026: Bridge program starts July 1